Capital Research Global Investors, a registered investment adviser, initiated a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 17,316,344 shares of the Healthcare company, valued at approximately $7.9B as of the filing date.
Vertex Pharmaceuticals Incorporated's stock currently trades at $461.24 with a market capitalization of $114.5B.
